In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has ...

Last year, the board voted to deem Enbrel “unaffordable,” setting up a months-long process of determining whether it should set a price ceiling.

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen (NASDAQ:AMGN) used certain patent-related tactics to extend its U.S. market dominance ...

Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District Court ...